81 related articles for article (PubMed ID: 17474469)
1. [Novel molecularly target therapies for leukemia].
Kiyoi H
Nihon Rinsho; 2007 Jan; 65 Suppl 1():611-6. PubMed ID: 17474469
[No Abstract] [Full Text] [Related]
2. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
3. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
4. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
5. [The present status of, and problems with the development of FLT3 kinase inhibitors].
Kiyoi H
Rinsho Ketsueki; 2006 Apr; 47(4):270-7. PubMed ID: 16715961
[No Abstract] [Full Text] [Related]
6. [New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Zhang GS
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):437-8. PubMed ID: 15854544
[No Abstract] [Full Text] [Related]
7. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
8. Acute leukemias in 2020: state of the art.
Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):384-385. PubMed ID: 32957743
[No Abstract] [Full Text] [Related]
9. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
10. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in the elderly.
Ho C; Butera JN
Med Health R I; 2011 Jan; 94(1):7-9. PubMed ID: 21290987
[No Abstract] [Full Text] [Related]
12. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
13. New agents for the treatment of AML recent study findings.
Gore SD
Clin Adv Hematol Oncol; 2008 Nov; 6(11):6-8. PubMed ID: 19205109
[No Abstract] [Full Text] [Related]
14. Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
Ōmura S; Asami Y; Crump A
J Antibiot (Tokyo); 2018 Aug; 71(8):688-701. PubMed ID: 29934602
[TBL] [Abstract][Full Text] [Related]
15. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
17. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
Bao T; Smith BD; Karp JE
Clin Adv Hematol Oncol; 2005 Apr; 3(4):287-96, 302. PubMed ID: 16167001
[TBL] [Abstract][Full Text] [Related]
18. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
[No Abstract] [Full Text] [Related]
19. FMS-like tyrosine kinase 3 inhibitors: a patent review.
Lee J; Paek SM; Han SY
Expert Opin Ther Pat; 2011 Apr; 21(4):483-503. PubMed ID: 21323612
[TBL] [Abstract][Full Text] [Related]
20. [Targeted therapy in hematologic neoplasia: overview].
Tauchi T; Ohyashiki K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():395-8. PubMed ID: 17474436
[No Abstract] [Full Text] [Related]
[Next] [New Search]
